Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...

NGS-based DPYD diplotype analysis beyond conventional targeted variant testing in an ethnically diverse cancer patient cohort. Deaths and Age-adjusted Mortality Rates (AAMRs) per 100,000 for trends ...

A WISDOM Study analysis shows that pathogenic variant testing can uncover high-risk women who may not qualify for earlier or more intensive breast screening under standard clinical and polygenic risk ...

Osimertinib plus anlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent gene alterations: A single-arm, prospective, multicenter phase II study. Safety ...